Press

Featured In

Labiotech.eu
May 22, 2024

The Undruggable Cancer Target: KRAS Inhibitors Move Ahead in the Clinic

Featured In

Santa Maria Local Health Unit
May 21, 2024

CEO of START Reinforces the Importance of the Santa Maria Phase 1 Oncology Trial Center

Featured In

HealthyWomen
May 20, 2024

The Connection Between Young Adults and Colon Cancer

Featured In

Clinical Leader
April 30, 2024

Early Exposure & Site Network Support Enable PI’s Enduring Interest in Research

Featured In

BusinessWire
April 29, 2024

First Patient Dosed with NILK-2301 in Phase I Clinical Trial

Featured In

BusinessWire
April 15, 2024

NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Contact Us
Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.